Zacks Small Cap Analysts Decrease Earnings Estimates for PLX

Protalix BioTherapeutics, Inc. (NYSE:PLX) – Stock analysts at Zacks Small Cap decreased their FY2026 earnings estimates for shares of Protalix BioTherapeutics in a research report issued to clients and investors on Tuesday, May 13th. Zacks Small Cap analyst J. Vandermosten now forecasts that the company will earn $0.74 per share for the year, down from their previous estimate of $0.84. The consensus estimate for Protalix BioTherapeutics’ current full-year earnings is $0.01 per share. Zacks Small Cap also issued estimates for Protalix BioTherapeutics’ FY2027 earnings at $1.15 EPS.

Other equities analysts have also issued reports about the stock. StockNews.com lowered shares of Protalix BioTherapeutics from a “strong-buy” rating to a “buy” rating in a report on Monday. HC Wainwright increased their target price on shares of Protalix BioTherapeutics from $10.00 to $15.00 and gave the stock a “buy” rating in a report on Monday, February 3rd.

Protalix BioTherapeutics Price Performance

NYSE:PLX opened at $1.67 on Thursday. The firm has a market capitalization of $132.94 million, a price-to-earnings ratio of -12.85 and a beta of -0.05. The company’s 50-day moving average is $2.48 and its two-hundred day moving average is $2.16. Protalix BioTherapeutics has a 1-year low of $0.82 and a 1-year high of $3.10.

Protalix BioTherapeutics (NYSE:PLX) last posted its earnings results on Friday, May 9th. The company reported ($0.05) earnings per share for the quarter. Protalix BioTherapeutics had a negative net margin of 21.03% and a negative return on equity of 30.89%.

Institutional Investors Weigh In On Protalix BioTherapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Y Intercept Hong Kong Ltd purchased a new position in shares of Protalix BioTherapeutics in the 4th quarter valued at $35,000. PFG Investments LLC purchased a new position in Protalix BioTherapeutics during the 4th quarter worth $39,000. Cubist Systematic Strategies LLC lifted its stake in shares of Protalix BioTherapeutics by 24.1% in the 4th quarter. Cubist Systematic Strategies LLC now owns 29,307 shares of the company’s stock worth $55,000 after acquiring an additional 5,686 shares during the period. Prudential Financial Inc. acquired a new stake in shares of Protalix BioTherapeutics in the 4th quarter worth $68,000. Finally, Point72 Asia Singapore Pte. Ltd. lifted its stake in shares of Protalix BioTherapeutics by 13.7% in the 4th quarter. Point72 Asia Singapore Pte. Ltd. now owns 53,507 shares of the company’s stock worth $101,000 after acquiring an additional 6,434 shares during the period. 16.53% of the stock is currently owned by institutional investors and hedge funds.

About Protalix BioTherapeutics

Protalix BioTherapeutics, Inc, a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally.